EA201990258A1 - Антитела к tim-3 - Google Patents

Антитела к tim-3

Info

Publication number
EA201990258A1
EA201990258A1 EA201990258A EA201990258A EA201990258A1 EA 201990258 A1 EA201990258 A1 EA 201990258A1 EA 201990258 A EA201990258 A EA 201990258A EA 201990258 A EA201990258 A EA 201990258A EA 201990258 A1 EA201990258 A1 EA 201990258A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tim
antibodies
mucin
monotherapy
chemotherapy
Prior art date
Application number
EA201990258A
Other languages
English (en)
Inventor
Кармин Карпенито
Ивэнь Ли
Ян Шэнь
И Чжан
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Priority claimed from PCT/US2017/047261 external-priority patent/WO2018039020A1/en
Publication of EA201990258A1 publication Critical patent/EA201990258A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Данное изобретение относится к антителам, которые связывают человеческий T-клеточный белок 3, содержащий домены иммуноглобулина и муцина (Tim-3), и могут быть пригодны для лечения солидных и гематологических опухолей как в качестве монотерапии, так и в комбинации с химиотерапией и ионизирующим излучением.
EA201990258A 2017-03-10 2017-08-17 Антитела к tim-3 EA201990258A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469753P 2017-03-10 2017-03-10
PCT/US2017/047261 WO2018039020A1 (en) 2016-08-25 2017-08-17 Anti-tim-3 antibodies

Publications (1)

Publication Number Publication Date
EA201990258A1 true EA201990258A1 (ru) 2019-07-31

Family

ID=67399635

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990258A EA201990258A1 (ru) 2017-03-10 2017-08-17 Антитела к tim-3

Country Status (1)

Country Link
EA (1) EA201990258A1 (ru)

Similar Documents

Publication Publication Date Title
EA201991156A1 (ru) АНТИТЕЛА К Tim-3 ДЛЯ КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1
JOP20190013A1 (ar) أجسام مضادة لـ (تي آي ام -3)
EA201890278A1 (ru) Антитела к pd-l1
EA202090204A1 (ru) Анти-cd137 антитела
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MY191649A (en) Antibodies to tigit
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
EA202092306A1 (ru) Анти-cd24 композиции и их применения
EA202192796A1 (ru) Tigit и pd-1/tigit-связывающие молекулы
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA201992145A1 (ru) Анти-pd-l1-анти-tim-3 биспецифические антитела
EA202092262A1 (ru) Антитела против cd137 для комбинации с антителами против pd-1
EA202092265A1 (ru) Антитела против cd137 для комбинации с антителами против pd-l1
EA201990258A1 (ru) Антитела к tim-3
EA202092279A1 (ru) Антитела к mica и/или micb и их применение